Rrmm Architects

Rrmm Architects company information, Employees & Contact Information

Explore related pages

Related company profiles:

RRMM Architects is recognized as a leading, dynamic design firm offering architectural, design build, interior design, and planning services. The firm's project experience encompasses schools, public safety facilities, secure federal facilities, higher education facilities, retail stores, and housing, among others. Licensed in 49 states, RRMM has successfully completed projects nationwide and worldwide while developing a reputation for comprehensive and imaginative designs and exceptional customer service.

Company Details

Employees
144
Founded
-
Address
1317 Executive Boulevard, Suite 200,united States
Phone
804.277.8991
Email
bk****@****rmm.com
Industry
Architecture And Planning
NAICS
Architectural Services
Website
rrmm.com
HQ
Chesapeake, VA
Looking for a particular Rrmm Architects employee's phone or email?

Rrmm Architects Questions

News

Linvoseltamab Plus Carfilzomib Shows Manageable Safety in RRMM - Targeted Oncology

Linvoseltamab Plus Carfilzomib Shows Manageable Safety in RRMM Targeted Oncology

Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM - CancerNetwork

Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM CancerNetwork

Anitocabtagene Autoleucel Demonstrates Deep, Durable Responses and Improved MRD-Negativity in RRMM - Pharmacy Times

Anitocabtagene Autoleucel Demonstrates Deep, Durable Responses and Improved MRD-Negativity in RRMM Pharmacy Times

Mastering the Relapsed Refractory Multiple Myeloma (RRMM) Treatment Landscape: Removing Barriers and Unleashing the Potential of CAR-T - European Medical Journal

Mastering the Relapsed Refractory Multiple Myeloma (RRMM) Treatment Landscape: Removing Barriers and Unleashing the Potential of CAR-T European Medical Journal

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple M - Business Wire

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple M Business Wire

What is Late-Line RRMM and How is it Determined? - Cure Today

What is Late-Line RRMM and How is it Determined? Cure Today

Lynozyfic wins FDA accelerated approval for treating RRMM adults - Rare Cancer News

Lynozyfic wins FDA accelerated approval for treating RRMM adults Rare Cancer News

Linvoseltamab Plus Carfilzomib Yields Deep, Durable Responses in Patients With RRMM - Pharmacy Times

Linvoseltamab Plus Carfilzomib Yields Deep, Durable Responses in Patients With RRMM Pharmacy Times

Talquetamab/Teclistamab Combo Shows High, Durable Responses in RRMM With EMD - Targeted Oncology

Talquetamab/Teclistamab Combo Shows High, Durable Responses in RRMM With EMD Targeted Oncology

Linvoseltamab, now Lynozyfic, earns EU’s conditional OK to treat RRMM - Rare Cancer News

Linvoseltamab, now Lynozyfic, earns EU’s conditional OK to treat RRMM Rare Cancer News

Talquetamab, Teclistamab Combo Yields Deep, Durable Responses for RRMM with EMD - Oncology News Central

Talquetamab, Teclistamab Combo Yields Deep, Durable Responses for RRMM with EMD Oncology News Central

Lisaftoclax Plus Pd Demonstrates Strong Response and Safety in RRMM - Targeted Oncology

Lisaftoclax Plus Pd Demonstrates Strong Response and Safety in RRMM Targeted Oncology

Patient With RRMM, Cytopenias, COPD, and Progressive Bone Disease - CancerNetwork

Patient With RRMM, Cytopenias, COPD, and Progressive Bone Disease CancerNetwork

Cell therapy anito-cel extends treatment-resistant RRMM survival - Rare Cancer News

Cell therapy anito-cel extends treatment-resistant RRMM survival Rare Cancer News

Sequencing Strategies and Patient Selection for Bispecific Antibodies in RRMM - CancerNetwork

Sequencing Strategies and Patient Selection for Bispecific Antibodies in RRMM CancerNetwork

Etentamig Shows Manageable Safety and Low Severe Infection Risk in RRMM - Pharmacy Times

Etentamig Shows Manageable Safety and Low Severe Infection Risk in RRMM Pharmacy Times

Teclistamab Efficacy Following Prior BCMA-Directed Therapy in RRMM - Targeted Oncology

Teclistamab Efficacy Following Prior BCMA-Directed Therapy in RRMM Targeted Oncology

FDA Grants ISB 2001 Fast Track Designation in RRMM - Targeted Oncology

FDA Grants ISB 2001 Fast Track Designation in RRMM Targeted Oncology

Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings - Targeted Oncology

Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings Targeted Oncology

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study | Blood Cancer Journal - Nature

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study | Blood Cancer Journal Nature

Analyzing Cohorts of Patients With RRMM in the CC-92480-MM-002 Trial - Targeted Oncology

Analyzing Cohorts of Patients With RRMM in the CC-92480-MM-002 Trial Targeted Oncology

Why Staging Matters With RRMM - HealthCentral

Why Staging Matters With RRMM HealthCentral

CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS - AJMC

CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS AJMC

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal - Nature

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal Nature

EHA 2025 Highlights: JNJ-5322 Trispecific Antibody in RRMM - Oncodaily

EHA 2025 Highlights: JNJ-5322 Trispecific Antibody in RRMM Oncodaily

How to Help Your RRMM Meds Work Better - HealthCentral

How to Help Your RRMM Meds Work Better HealthCentral

Fifth Time’s a Charm for RRMM - HealthCentral

Fifth Time’s a Charm for RRMM HealthCentral

What Your Hematologist Wants You to Know About RRMM - HealthCentral

What Your Hematologist Wants You to Know About RRMM HealthCentral

Real-world analysis of teclistamab in 123 RRMM patients from Germany - Leukemia - Nature

Real-world analysis of teclistamab in 123 RRMM patients from Germany - Leukemia Nature

Elranatamab Generates Deep and Durable Early Responses in RRMM - Targeted Oncology

Elranatamab Generates Deep and Durable Early Responses in RRMM Targeted Oncology

Isatuximab Shows Tolerability in Real-World Population With RRMM - Targeted Oncology

Isatuximab Shows Tolerability in Real-World Population With RRMM Targeted Oncology

FDA Clears IND for CT071 in RRMM and Primary Plasma Cell Leukemia - Targeted Oncology

FDA Clears IND for CT071 in RRMM and Primary Plasma Cell Leukemia Targeted Oncology

The RRMM Patient Journey: Part 1 - AJMC

The RRMM Patient Journey: Part 1 AJMC

Introduction to the CC-92480-MM-002 Trial of Mezigdomide in RRMM - Targeted Oncology

Introduction to the CC-92480-MM-002 Trial of Mezigdomide in RRMM Targeted Oncology

Talquetamab, Cevostamab and Elranatamab in RRMM - OncLive

Talquetamab, Cevostamab and Elranatamab in RRMM OncLive

Daratumumab With Bortezomib and Dexamethasone Improves Survival in RRMM - Targeted Oncology

Daratumumab With Bortezomib and Dexamethasone Improves Survival in RRMM Targeted Oncology

FDA declines linvoseltamab decision for RRMM due to facility issue - Rare Cancer News

FDA declines linvoseltamab decision for RRMM due to facility issue Rare Cancer News

FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM - Rare Cancer News

FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM Rare Cancer News

EU committee recommends Blenrep combos for approval in RRMM - Rare Cancer News

EU committee recommends Blenrep combos for approval in RRMM Rare Cancer News

Treatment Approaches for Heavily Pretreated RRMM - CancerNetwork

Treatment Approaches for Heavily Pretreated RRMM CancerNetwork

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) | Blood Cancer Journal - Nature

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) | Blood Cancer Journal Nature

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study - Nature

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study Nature

Regeneron seeking approval of linvoseltamab for RRMM in US, EU - Rare Cancer News

Regeneron seeking approval of linvoseltamab for RRMM in US, EU Rare Cancer News

Phase 3 trial of CAR T-cell therapy anito-cel for RRMM opens - Rare Cancer News

Phase 3 trial of CAR T-cell therapy anito-cel for RRMM opens Rare Cancer News

Top Rrmm Architects Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant